CYBN
Price
$8.15
Change
-$0.43 (-5.01%)
Updated
Jun 27 closing price
Capitalization
173.36M
RXRX
Price
$5.03
Change
-$0.37 (-6.85%)
Updated
Jun 27 closing price
Capitalization
2.04B
43 days until earnings call
Interact to see
Advertisement

CYBN vs RXRX

Header iconCYBN vs RXRX Comparison
Open Charts CYBN vs RXRXBanner chart's image
Cybin
Price$8.15
Change-$0.43 (-5.01%)
Volume$184.17K
Capitalization173.36M
Recursion Pharmaceuticals
Price$5.03
Change-$0.37 (-6.85%)
Volume$46.63M
Capitalization2.04B
CYBN vs RXRX Comparison Chart in %
Loading...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYBN vs. RXRX commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYBN is a Buy and RXRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (CYBN: $8.15 vs. RXRX: $5.03)
Brand notoriety: CYBN and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYBN: 64% vs. RXRX: 190%
Market capitalization -- CYBN: $173.36M vs. RXRX: $2.04B
CYBN [@Biotechnology] is valued at $173.36M. RXRX’s [@Biotechnology] market capitalization is $2.04B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYBN’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • CYBN’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, both CYBN and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYBN’s TA Score shows that 3 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).

  • CYBN’s TA Score: 3 bullish, 5 bearish.
  • RXRX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than CYBN.

Price Growth

CYBN (@Biotechnology) experienced а +4.76% price change this week, while RXRX (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

RXRX is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.05B) has a higher market cap than CYBN($173M). CYBN YTD gains are higher at: -7.596 vs. RXRX (-25.592). CYBN has higher annual earnings (EBITDA): -134.52M vs. RXRX (-524.77M). RXRX has more cash in the bank: 500M vs. CYBN (136M). CYBN has less debt than RXRX: CYBN (0) vs RXRX (92.9M). RXRX has higher revenues than CYBN: RXRX (59.8M) vs CYBN (0).
CYBNRXRXCYBN / RXRX
Capitalization173M2.05B8%
EBITDA-134.52M-524.77M26%
Gain YTD-7.596-25.59230%
P/E RatioN/AN/A-
Revenue059.8M-
Total Cash136M500M27%
Total Debt092.9M-
TECHNICAL ANALYSIS
Technical Analysis
CYBNRXRX
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
84%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
87%
MACD
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
84%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 14 days ago
90%
Bearish Trend 18 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JMPLY47.96N/A
N/A
Johnson Matthey plc
QIFTF0.58N/A
N/A
Quorum Information Technologies Inc.
ROIUF0.07N/A
N/A
Route1 Inc.
PLRRF5.98N/A
N/A
Polar Capital Holdings PLC
CRHKY6.33-0.06
-0.94%
China Resources Beer Holdings Company Limited

CYBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYBN has been loosely correlated with ATAI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CYBN jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
-5.01%
ATAI - CYBN
46%
Loosely correlated
-2.22%
ABSI - CYBN
39%
Loosely correlated
-3.32%
RXRX - CYBN
39%
Loosely correlated
-6.85%
ABCL - CYBN
39%
Loosely correlated
-3.48%
EYPT - CYBN
35%
Loosely correlated
-7.04%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been closely correlated with CRSP. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-6.85%
CRSP - RXRX
72%
Closely correlated
N/A
BEAM - RXRX
64%
Loosely correlated
-1.98%
ABSI - RXRX
62%
Loosely correlated
-3.32%
ABCL - RXRX
59%
Loosely correlated
-3.48%
PRME - RXRX
57%
Loosely correlated
-8.68%
More